123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 10, 2012, Pages 1609-1617

  Noordzij, Walter ^a   Glaudemans, Andor W J M ^a   Van Rheenen, Ronald W J ^a   Hazenberg, Bouke P C ^b   Tio, René A ^b   Dierckx, Rudi A J O ^a   Slart, Riemer H J A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amyloidosis; Cardiac; Echocardiography; MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMYLOID;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SCINTIGRAPHY; SYMPATHETIC NERVE;

3-IODOBENZYLGUANIDINE; AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; GATED BLOOD-POOL IMAGING; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; NERVE ENDINGS; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84868193794     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2187-8     Document Type: Article

References (22)

1. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141-57.
2. Falk RH, Plehn J, Deering T, Schick EC Jr., Boinay P, Rubinow A, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59:418-22.
3. Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16:1135-41.
4. Nakata T, Shimamoto K, Yonekura S, Kobayashi N, Sugiyama T, Imai K, et al. Cardiac sympathetic denervation in transthyretinrelated familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med. 1995;36:1040-2.
5. Tanaka M, HongoM, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29:168-74.
6. Delahaye N, Dinanian S, SlamaMS,Mzabi H, Samuel D, Adams D, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med. 1999;26:416-24.
7. Arbab AS, Koizumi K, Toyama K, Arai T, Yoshitomi T, Araki T. Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med. 1997;11:139-41.
8. Delahaye N, Rouzet F, Sarda L, Tamas C, Dinanian S, Plante-Bordeneuve V, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine. 2006;85:229-38.
9. Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J. 2002;144:122-9.
10. Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009;36:702-14.
11. Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123Imetaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802-12.
12. van der Vleuten PA, Slart RH, Tio RA, van der Horst IC, van Veldhuisen DJ, Dierckx RA, Zijlstra F. The feasibility of repeated left ventricular ejection fraction analysis with sequential singledose radionuclide ventriculography. Nucl Med Commun. 2005;26:711-5.
13. Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of 123I labelled- metaiodobenzylguanidine uptake using dual energy window method: feasibility of correction with different cameracollimator combinations. Eur J Nucl Med Mol Imaging. 2009;35:560-66.
14. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425-9.
15. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
16. Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551-7.
17. Sasano T, Abraham R, Chang KC, Ashikaga H, Mills KJ, Holt DP, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266-75.
18. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603-16.
19. Matsunari I, Aoki H, Nomura Y, Takeda N, Chen WP, Taki J, et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging. 2010;3:595-603.
20. Raffel DM, Jung YW, Gildersleeve DL, Sherman PS, Moskwa JJ, Tluczek LJ, et al. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem. 2007;50:2078-88.
21. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-31.
22. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225-33.